Why ImmunityBio Inc. (IBRX) Skyrocketed On Monday?

We recently published a list of Biotech Stocks Dominate Monday’s Top 10 Gainers. In this article, we are going to take a look at where ImmunityBio Inc. (NASDAQ:IBRX) stands against other biotech stocks that dominate Monday’s top gainers.

The stock market kicked off the shortened trading week on a positive note, with Wall Street’s major indices finishing in the green following President Donald Trump’s temporary tax reprieve on technology companies.

The S&P 500 recorded the highest gain, up 0.79 percent, while the Dow Jones came second at 0.78 percent. The tech-heavy Nasdaq was also up by 0.64 percent.

Benchmark indices aside, 10 companies dominated by biotechnology firms mirrored the broader market optimism, recording modest gains during the session.

In this article, let us explore Monday’s top 10 gainers and the reasons behind their gains.

To come up with the list, we only considered the stocks with $2 billion market capitalization and $5 million trading volume.

A technician analyzing natural killer cells, as part of an immune system study and research into therapeutical agents.

ImmunityBio Inc. (NASDAQ:IBRX)

ImmunityBio grew for a second day on Monday as investor funds started flocking to stocks with lesser risks from the ongoing trade tensions globally while repositioning portfolios ahead of its Investor Day tomorrow, April 15.

According to the company, it plans to announce in-depth updates about its business operations, key timelines, ongoing clinical trials, and recent research and development advancements.

IBRX is a clinical-stage biotech company developing immune-enhancing therapies for cancer and infectious diseases. It is underway with its global expansion for its novel immunotherapy ANKTIVA, which aims to treat unresponsive non-muscle invasive bladder cancer carcinoma in situ (CIS).

Just recently, IBRX submitted a marketing authorization request from the European Medicines Agency for the review and assessment of ANKTIVA. If approved by the EMA, IBRX would be able to sell ANKTIVA in 27 countries in Europe, including Norway, Iceland, and Liechtenstein.

Overall, IBRX ranks 7th on our list of biotech stocks that dominate Monday’s top gainers. While we acknowledge the potential of IBRX as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than IBRX but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.